Christine A Bricault, James M Kovacs, Alexander Badamchi-Zadeh, Krisha McKee, Jennifer L Shields, Bronwyn M Gunn, George H Neubauer, Fadi Ghantous, Julia Jennings, Lindsey Gillis, James Perry, Joseph P Nkolola, Galit Alter, Bing Chen, Kathryn E Stephenson, Nicole Doria-Rose, John R Mascola, Michael S Seaman, Dan H Barouch
A vaccination regimen capable of eliciting potent and broadly neutralizing antibodies (bNAbs) remains an unachieved goal of the HIV-1 vaccine field. Here we report the immunogenicity of longitudinal prime/boost vaccination regimens over a period of 200 weeks in guinea pigs with a panel of HIV-1 envelope (Env) gp140 protein immunogens. We assessed vaccine regimens that included a monovalent clade C gp140 regimen (C97), a tetravalent regimen consisting of four clade C gp140s (4C), and a tetravalent regimen consisting of a clade A, B, C, and mosaic gp140 (ABCM)...
April 11, 2018: Journal of Virology